Newsroom | 5128 results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today celebrated the groundbreaking of its new state-of-the-art research, development, and manufacturing facility in Huntsville, Alabama. The new site represents a major milestone in the company’s commitment to strengthening U.S. manufacturing, creating high-quality j...

紐約--(BUSINESS WIRE)--(美國商業資訊)-- 身為STAAR Surgical Company（簡稱「STAAR」或「公司」）(NASDAQ: STAA)約27.5%已發行普通股的持有者，Broadwood Partners, L.P.及其附屬公司（統稱「Broadwood」）今日宣布已向美國證券交易委員會（簡稱「SEC」）遞交最終代理聲明和綠色代理卡，並就反對Alcon Inc. (NYSE: ALC)附屬公司擬按2025年8月5日公布的條款收購公司（簡稱「擬議合併」）一事致信其他股東。 以下是Broadwood信件的全文。 * * * 2025年9月24日 尊敬的STAAR Surgical股東： Broadwood Partners,L.P.及其附屬公司（統稱「Broadwood」或「我們」）三十多年來一直是STAAR Surgical Company（簡稱「STAAR」或「公司」）的忠實投資人和堅定支持者。我們曾多次為公司提供所需資金，並逐步在公開市場增持大量股份，最近一次增持發生在幾個月前。目前，我們實益擁有STAAR約27.5%的已發行股份，成為公司最大的...

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) today announced that it has filed a definitive proxy statement and GREEN proxy card with the U.S. Securities and Exchange Commission (the “SEC”) and sent a letter to its fellow stockholders in connection with its opposition to the proposed acquisition of the Company b...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Horizon Surgical Systems, a leader in surgical robotic platforms, appoints Rajesh K. Rajpal, MD as its Chief Strategy and Medical Officer (CSO & CMO)....

DUBLIN--(BUSINESS WIRE)--The "Enterprise Tech Ecosystem Series: EssilorLuxottica SA 2025" company profile has been added to ResearchAndMarkets.com's offering. The report provides detailed information and insights into EssilorLuxottica's technology activities, highlighting its digital transformation strategies and innovation programs. It offers an overview of key technology initiatives, including partnerships, product launches, and acquisitions, with analysis of each initiative’s theme, objectiv...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Character Biosciences, a precision medicine company transforming drug development for polygenic diseases, today announced that Fierce Biotech has named it as one of 2025’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising private biotechnology companies in the industry. “Being named to the Fierce 15 is a recognition of the bold science our team is advancing to change the course of age-related eye disease...

SOUTHLAKE, Texas--(BUSINESS WIRE)--Retina Consultants of America (RCA), a leading management services organization of retina specialists, today announced the addition of The Retina Institute (TRI) to its nationwide network. The St. Louis-based practice serves more than 40,000 patients across Missouri and Illinois, specializing in the treatment of diseases and disorders affecting the retina, vitreous and macula. “TRI is renowned for its dedication to advancing the retina specialty, highlighted b...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the 45-day “window shop” period under the terms of the previously announced merger agreement with affiliates of Alcon (SIX/NYSE: ALC). The “window shop” period expired at 11:59 p.m., Eastern Time, on September 19, 2025, and no competing acquisition proposal was receive...

HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR”) (NASDAQ:STAA), today announced its opposition to the Company’s proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025. Yunqi Capital released the following open letter to fellow STAAR shareholders explaining why it opposes the transaction: September 22, 2025...

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems, Inc. (“iVeena”), a clinical-stage ophthalmology company, today announced it has been awarded a $2 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH). The funding will advance the development of novel topical eye drops being investigated to control pediatric myopia and other refractive disorders. iVeena’s research is led by Sarah Molokhia, PhD, V...